Should I buy or sell Bausch + Lomb stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BLCO shares. View BLCO analyst ratings or view top-rated stocks .

What is Bausch + Lomb's stock price target for 2024?

8 Wall Street analysts have issued 12 month price targets for Bausch + Lomb's stock. Their BLCO share price targets range from $16.00 to $25.00. On average, they predict the company's share price to reach $20.10 in the next year. This suggests a possible upside of 30.1% from the stock's current price. View analysts price targets for BLCO or view top-rated stocks among Wall Street analysts .

How have BLCO shares performed in 2023?

Bausch + Lomb's stock was trading at $15.51 at the beginning of the year. Since then, BLCO stock has decreased by 0.4% and is now trading at $15.45. View the best growth stocks for 2023 here .

Are investors shorting Bausch + Lomb?

Bausch + Lomb saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,840,000 shares, an increase of 10.0% from the October 31st total of 3,490,000 shares. Based on an average trading volume of 385,900 shares, the days-to-cover ratio is presently 10.0 days. Currently, 10.0% of the company's shares are sold short. View Bausch + Lomb's Short Interest .

When is Bausch + Lomb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our BLCO earnings forecast .

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) released its quarterly earnings results on Wednesday, November, 1st. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.04. The company earned $1.01 billion during the quarter, compared to the consensus estimate of $990.68 million. Bausch + Lomb had a positive trailing twelve-month return on equity of 3.63% and a negative net margin of 5.22%. The company's revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.31 earnings per share.

What ETFs hold Bausch + Lomb's stock?

ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT) . First Trust US Equity Opportunities ETF (FPX) .

When did Bausch + Lomb IPO?

(BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

Who are Bausch + Lomb's major shareholders?

Bausch + Lomb's stock is owned by a number of retail and institutional investors. Top institutional investors include Eminence Capital LP (1.71%), Goldentree Asset Management LP (1.44%), Maple Rock Capital Partners Inc. (0.92%), River Road Asset Management LLC (0.45%), Alberta Investment Management Corp (0.39%) and Laurion Capital Management LP (0.29%).

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Bausch + Lomb Stock Price, News & Analysis (NYSE:BLCO)

$15.55

+0.10 (+0.65%)

(As of 02:26 PM ET)

Compare

Today's Range: $15.06
▼
$15.66
50-Day Range: $14.87
▼
$17.57
52-Week Range: $14.37
▼
$21.95

Volume: 372,010 shs
Average Volume: 411,028 shs
Market Capitalization: $5.46 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.35

Bausch + Lomb MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 30.1% Upside
$20.10 Price Target
Short Interest: Bearish
9.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.12
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -1.54%
From $0.65 to $0.64 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.34 out of 5 stars

Medical Sector

912th out of 951 stocks

Ophthalmic Goods Industry

6th out of 6 stocks

3.3

Analyst's Opinion

Consensus Rating
Bausch + Lomb has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.10, Bausch + Lomb has a forecasted upside of 30.1% from its current price of $15.45.
Amount of Analyst Coverage
Bausch + Lomb has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
9.97% of the float of Bausch + Lomb has been sold short.
Short Interest Ratio / Days to Cover
Bausch + Lomb has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
Change versus previous month
Short interest in Bausch + Lomb has recently increased by 10.03%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Bausch + Lomb does not currently pay a dividend.
Dividend Growth
Bausch + Lomb does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLCO.

1.0

News and Social Media Coverage

News Sentiment
Bausch + Lomb has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Bausch + Lomb this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for BLCO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bausch + Lomb insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 12.45% of the stock of Bausch + Lomb is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Bausch + Lomb are expected to decrease by -1.54% in the coming year, from $0.65 to $0.64 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bausch + Lomb is -26.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bausch + Lomb is -26.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Bausch + Lomb has a PEG Ratio of 11.08. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bausch + Lomb has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bausch + Lomb Stock (NYSE:BLCO)

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BLCO Stock News Headlines

December 2, 2023 | americanbankingnews.com

Bausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of "Moderate Buy" from Analysts

November 29, 2023 | americanbankingnews.com

Bausch + Lomb (NYSE:BLCO) Price Target Cut to $17.00 by Analysts at Barclays

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 28, 2023 | finance.yahoo.com

Bausch + Lomb CEO Brent Saunders Pays $35.35 Million for Cher’s Former Miami Beach Home

November 15, 2023 | finance.yahoo.com

Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

November 8, 2023 | seekingalpha.com

Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)

November 7, 2023 | morningstar.com

Bausch & Lomb Corp BLCO

November 3, 2023 | markets.businessinsider.com

Bausch + Lomb Corporation: Strong Q3 Performance and Promising Investments Justify Buy Rating Despite Challenges

December 4, 2023 | Edge On The Street (Ad)

Is This The Most Overlooked Gold Investment Strategy of 2024?

There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.

November 1, 2023 | finance.yahoo.com

Bausch + Lomb (BLCO) Reports Q3 Earnings: What Key Metrics Have to Say

November 1, 2023 | markets.businessinsider.com

Bausch + Lomb Q3 Adj. Profit Declines; Revenues Up 8% On Constant Currency Basis

November 1, 2023 | finance.yahoo.com

Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance

November 1, 2023 | finance.yahoo.com

Bausch & Lomb Corp (BLCO) Reports Q3 2023 Earnings and Raises Full-Year Guidance

October 26, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: CareMax (CMAX), Bausch + Lomb Corporation (BLCO) and Arcus Biosciences (RCUS)

October 26, 2023 | finance.yahoo.com

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting

October 25, 2023 | finance.yahoo.com

Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

October 17, 2023 | markets.businessinsider.com

Bausch + Lomb’s Promising Future: A Buy Recommendation Based on New Drug Launch and Potential Synergies

October 16, 2023 | finance.yahoo.com

Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1

October 14, 2023 | msn.com

Morgan Stanley Maintains Bausch + Lomb (BLCO) Equal-Weight Recommendation

October 13, 2023 | markets.businessinsider.com

Hold Rating on Bausch + Lomb Amidst Anticipated Transitional Year and Competitive Dynamics

October 6, 2023 | markets.businessinsider.com

Promising Growth Potential for Bausch + Lomb: Impact of XIIDRA Acquisition and MIEBO Launch

October 4, 2023 | msn.com

Evercore ISI Group Reiterates Bausch + Lomb (BLCO) Outperform Recommendation

October 4, 2023 | finance.yahoo.com

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

October 3, 2023 | markets.businessinsider.com

6 Analysts Have This to Say About Bausch & Lomb

September 26, 2023 | finance.yahoo.com

Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States

September 21, 2023 | msn.com

Bausch Health stock rebounds from Tuesday sell-off, helped by Jefferies upgrade

September 20, 2023 | cnbc.com

Buy this pharma stock that could more than double if it clears a legal battle, Jefferies says

See More Headlines

Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Ophthalmic goods
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:BLCO
CUSIP: N/A
CIK: 1860742
Web: www.bausch.com
Phone: 905-695-7700
Fax: N/A
Employees: 12,900
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.10
High Stock Price Target: $25.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +31.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 23.77
P/E Growth: 11.08
Net Income: $6 million
Net Margins: -5.22%
Pretax Margin: -2.80%
Return on Equity: 3.63%
Return on Assets: 2.18%

Debt

Debt-to-Equity Ratio: 0.64
Current Ratio: 1.78
Quick Ratio: 1.23

Sales & Book Value

Annual Sales: $3.77 billion
Price / Sales: 1.44
Cash Flow: $2.18 per share
Price / Cash Flow: 7.10
Book Value: $20.29 per share
Price / Book: 0.76

Miscellaneous

Outstanding Shares: 350,860,000
Free Float: N/A
Market Cap: $5.42 billion
Optionable: Not Optionable
Beta: 0.20

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Osama A. Eldessouky (Age 51)
Executive VP & CFO
Comp: $1.09M
Dr. Yehia Hashad M.D. (Age 56)
Executive VP of Research & Development and Chief Medical officer
Comp: $1.09M
Mr. Brenton L. Saunders J.D. (Age 53)
CEO & Chairman
Mr. Alan Waterhouse CPFA (Age 63)
MBA, Executive VP and Chief Supply Chain & Operations Officer
Mr. Frederick J. Munsch (Age 53)
Senior VP, Controller & Chief Accounting Officer
Mr. A. Robert D. Bailey (Age 60)
Executive VP & Chief Legal Officer
Mr. Jonathon L. Kellerman
Chief Compliance Officer
T.J. Crawford
Chief Communications Officer
Dr. Manisha A. Narasimhan Ph.D. (Age 46)
Chief Corporate Development & Digital Officer
Ms. Asli Gevgilili
Executive VP & Chief Human Resources Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BLCO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bausch + Lomb stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BLCO shares.
View BLCO analyst ratings or view top-rated stocks.
What is Bausch + Lomb's stock price target for 2024?: 8 Wall Street analysts have issued 12 month price targets for Bausch + Lomb's stock. Their BLCO share price targets range from $16.00 to $25.00. On average, they predict the company's share price to reach $20.10 in the next year. This suggests a possible upside of 30.1% from the stock's current price.
View analysts price targets for BLCO or view top-rated stocks among Wall Street analysts.
How have BLCO shares performed in 2023?: Bausch + Lomb's stock was trading at $15.51 at the beginning of the year. Since then, BLCO stock has decreased by 0.4% and is now trading at $15.45.
View the best growth stocks for 2023 here.
Are investors shorting Bausch + Lomb?: Bausch + Lomb saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,840,000 shares, an increase of 10.0% from the October 31st total of 3,490,000 shares. Based on an average trading volume of 385,900 shares, the days-to-cover ratio is presently 10.0 days. Currently, 10.0% of the company's shares are sold short.
View Bausch + Lomb's Short Interest.
When is Bausch + Lomb's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our BLCO earnings forecast.
How were Bausch + Lomb's earnings last quarter?: Bausch + Lomb Co. (NYSE:BLCO) released its quarterly earnings results on Wednesday, November, 1st. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.04. The company earned $1.01 billion during the quarter, compared to the consensus estimate of $990.68 million. Bausch + Lomb had a positive trailing twelve-month return on equity of 3.63% and a negative net margin of 5.22%. The company's revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.31 earnings per share.

What ETFs hold Bausch + Lomb's stock?: ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT).First Trust US Equity Opportunities ETF (FPX).
When did Bausch + Lomb IPO?: (BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.
Who are Bausch + Lomb's major shareholders?: Bausch + Lomb's stock is owned by a number of retail and institutional investors. Top institutional investors include Eminence Capital LP (1.71%), Goldentree Asset Management LP (1.44%), Maple Rock Capital Partners Inc. (0.92%), River Road Asset Management LLC (0.45%), Alberta Investment Management Corp (0.39%) and Laurion Capital Management LP (0.29%).
How do I buy shares of Bausch + Lomb?: Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:BLCO) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bausch + Lomb Stock Price, News & Analysis (NYSE:BLCO)

Bausch + Lomb MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Bausch + Lomb Stock (NYSE:BLCO)

BLCO Stock Price History

BLCO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

BLCO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™